Who is typically assessed for ChondroFiller at the ankle?

Most people assessed for ChondroFiller at the ankle share a similar clinical picture: a focal cartilage lesion on the talar dome — typically post-traumatic or osteochondritis dissecans — that has persisted despite at least six months of conservative care such as physiotherapy, activity modification, and bracing. The scaffold is a CE-marked injectable collagen device placed under ultrasound guidance in an outpatient clinic; it promotes endogenous repair by recruiting the patient's own progenitor cells into the treated area.

Symptoms matter as much as the scan. Candidates usually report pain and function loss anatomically confined to the tibiotalar joint, consistent with what the MRI shows. Diffuse ankle pain, or symptoms that do not correspond to the imaged lesion, suggest a different underlying cause and prompt further assessment.

Certain features make ChondroFiller unsuitable. Active joint infection, known collagen hypersensitivity, and end-stage tibiotalar osteoarthritis are hard exclusions — the 3–5-year hip cohort data are instructive here, with uniformly poor results once significant pre-existing joint degeneration is present. Mechanical factors such as lower-limb alignment and ankle ligament integrity also influence candidacy, and a specialist will assess both as part of pre-treatment planning; these are covered in detail later in this article.

Overall, the strongest candidates tend to be active adults with a contained, symptomatic lesion who want to avoid an operating theatre.

MRI findings that make a talar lesion eligible

Four features on MRI determine whether a talar lesion sits within the ChondroFiller scaffold pathway.

Cartilage quality and demarcation. The scan should show a focal, well-delimited full-thickness defect on the talar dome — ICRS or Outerbridge Grade III or IV — with the surrounding cartilage remaining structurally healthy. The "well-delimited" detail matters: the scaffold needs a stable rim of intact cartilage to contain the gel as it sets in situ; a defect with ragged, deteriorating edges is less likely to hold the material precisely in place.

Subchondral bone status. The bone plate directly beneath the defect must be intact or only minimally involved. Large or deep subchondral cysts, and any evidence of bone-plate collapse, are disqualifying — if the underlying bone has given way structurally, the scaffold has no stable base to adhere to.

Joint-space preservation. The tibiotalar joint space must be maintained on MRI. Significant narrowing points to generalised osteoarthritis rather than a focal lesion, a distinction that matters clinically: long-term hip cohort data show consistently poor outcomes once meaningful joint degeneration is already present, and the same principle applies to the ankle.

Defect size. Size is the most practically decisive criterion. Ankle-specific clinical protocols target lesions within approximately 150 mm² — equivalent to roughly 1.5 cm² or a 15 mm average diameter. The published JFASAP 2025 talar OLT study used a slightly more conservative formal inclusion threshold of less than 1.2 cm², so the two figures are broadly aligned rather than contradictory, with the study representing the tighter end of a similar range. A single ChondroFiller preparation covers defects up to 3 cm²; multi-unit use is possible for larger areas, though ankle-specific controlled evidence in that range remains limited.

How the ankle injection is performed

The appointment takes place in a clinic room, not an operating theatre — there is no incision, no general anaesthetic, and the whole session typically runs between 30 and 45 minutes.

Before the gel is placed, the clinician positions an ultrasound probe over the ankle to visualise the tibiotalar joint in real time. The joint space at the ankle is constrained, and the route to the talar dome passes close to structures including the dorsalis pedis artery and branches of the tibial nerve. Continuous imaging allows the needle to be steered safely around these structures and into the correct position within the defect — confirming accurate placement before any material is released.

ChondroFiller is supplied in a dual-chamber syringe. As the needle advances, the liquid collagen and a neutralising agent mix at the tip and enter the defect as a liquid. Within three to five minutes the material self-gels and conforms to the shape of the cavity. Because the gel cannot be moved or adjusted once it has left the needle, continuous image-guided placement throughout delivery is essential rather than a precautionary extra.

After the injection, weight-bearing on the treated ankle is kept to a minimum for an initial period. Biomechanical data indicate that the scaffold is not mechanically stable immediately after placement and does not adequately protect the opposing joint surface during loading until stable filling has been achieved. Patients are given clear guidance on this before leaving the clinic.

Why whole-leg alignment affects ankle candidacy

Cartilage candidacy assessment does not end with the MRI scan. The angle and loading pattern of the leg determine how forces travel through the tibiotalar joint — and a scaffold placed into a joint that continues to concentrate load on the defect abnormally is at risk of failure regardless of how well the lesion itself meets the imaging criteria.

A 2025 study of 52 talar osteochondral lesions found that lower-limb alignment and lesion location are closely linked rather than independent: varus malalignment independently predicted medial talar lesions — which account for around 83% of all talar OLTs — while valgus alignment independently predicted lateral lesions, with an odds ratio of 2.63. Talar tilt was also independently associated with lesion side. These findings suggest that alignment partly explains why a lesion develops where it does; correcting that pattern before or alongside treatment is therefore mechanically grounded, not an administrative formality.

Untreated chronic ankle instability carries the same load-concentration risk and is reviewed for the same reason. Both are assessed as a standard part of specialist evaluation before a scaffold pathway is confirmed — the alignment and stability picture determines the sequencing and whether any adjunct procedure is needed alongside ChondroFiller, not simply whether the patient is in or out.

What the clinical evidence shows — and where gaps remain

Three layers of evidence inform how specialists currently frame ChondroFiller candidacy at the ankle: the mechanism, the multi-joint clinical record, and the ankle-specific data that is still building.

Mechanism. The scaffold's cell-recruiting action has been directly measured. An ex vivo osteochondral study recorded a 2.4-fold increase in DNA content within the collagen matrix by day 14, confirming that progenitor cells migrate from the surrounding synovium and subchondral bone into the gel. That is acellular matrix-induced chondrogenesis — a recruited-cell process, not a pre-loaded cell therapy.

Knee evidence. The strongest clinical outcomes come from randomised and cohort knee studies. IKDC scores — a validated patient-reported function measure covering pain, stiffness, and activity level — improved significantly from baseline at 3, 6, and 12 months (p<0.05). MOCART imaging assessments, which grade how completely a defect is filled and how well new tissue integrates with adjacent cartilage on MRI, showed progressive maturation from adequate early filling to more developed tissue architecture at one year.

Hip signal. A 3–5-year hip cohort (n=21 at follow-up) found 17 patients achieved good or excellent outcomes. Every patient with pre-existing Tönnis grade 2–3 disease — a radiographic classification for moderate-to-severe joint degeneration — had a poor result. That finding maps directly onto ankle candidacy: preserved tibiotalar joint space is a prerequisite, not merely a preference.

Ankle position. Published ankle-specific data are currently limited to a small case series (JFASAP, 2025) and DGOU registry observations noting that ankle ChondroFiller evidence is less mature than for AMIC/Chondro-Gide scaffolds. No controlled ankle trial has established an ideal lesion size for the talar dome; the 150 mm² threshold used clinically is protocol-derived rather than RCT-validated. A reported complaint rate of approximately 0.06% across treated cases is consistent with a favourable safety profile, though it should not be read as a proxy for efficacy.

Finding a specialist and questions worth asking

Three questions are worth raising at any specialist assessment for talar ChondroFiller.

Has the MRI been reviewed for subchondral bone plate status — not just cartilage grade? An intact bone plate is what gives the scaffold a stable base; a large or deep cyst changes the candidacy picture even when the overlying cartilage damage looks contained.

Has whole-leg alignment been formally assessed? As the 2025 study of 52 talar osteochondral lesions demonstrated, malalignment and lesion location are mechanically linked — a scaffold placed into a joint that continues to concentrate load abnormally is at risk regardless of injection precision.

Is ChondroFiller the right standalone approach, or does the defect size, bone involvement, or ankle stability picture suggest a combined plan? The answer shapes the rehabilitation structure as much as the injection itself.

Finding a specialist who offers ankle cartilage assessment and ChondroFiller injection is the practical next step; Search MSK lists practitioners across the UK — filtering by region and specialty narrows the list to those with relevant experience in this presentation.

For well-selected patients, published knee series show significant improvement in function scores at 3, 6, and 12 months, with MOCART imaging confirming progressive cartilage maturation to one year. Ankle-specific data are still maturing, but candidacy precision — the rigour of pre-injection assessment — is the variable most within a patient's influence going into this pathway.